中生制药(01177)尾盘涨超6%，截至发稿，涨5.97%，报4.44港元，成交额5.53亿港元。

消息面上，中生制药宣布，公司在2025年美国临床肿瘤学会(ASCO)年会上公布了TQB2102“HER2双特异性抗体偶联药物(ADC)”的首次人体I期临床研究初步数据。截止2024年10月1日，该试验共纳入181例经治无标准治疗方案的晚期实体瘤患者。

美银证券研究报告指，基于中国生物制药更多临床疗效证据及今年3月的强劲销售表现，加上该公司宣布QP001(美洛昔康注射液)近期获得中国NMPA及美国FDA上市批准等利好因素，将中国生物制目标价从4.4元上调至5.1元，重申“买入”评级。QP001是中国首个每日一次的长效镇痛非甾体抗炎药(NSAID)注射液，因此该行上调QP001的收入预测以反映获批影响。

海量资讯、精准解读，尽在新浪财经APP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.